Fundraising FoxVetDC
Castle Rock, US · Founded 2012 · Delaware corporation · 1 known investors
Find your way into VetDC
Sign up to see every warm intro you have to VetDC
- Paths you didn't know you had: your email and LinkedIn already hold routes to the VetDC team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A veterinary pharmaceutical company developing Rabacfosadine, an acyclic nucleotide analogue for treating lymphoma in dogs and cats.
Founders & leadership
SB
Steve Bryan WarneckeExecutive
SJ
Steven J RoyNamed on SEC filing
Board
TR
T. Richard FortBoard director
ML
Mark LupaBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.7M disclosed across 2 rounds · 2014–2015
▶$2.1MraisedMar 2015 · 35 investors · BiotechnologyRule 506(b)
▶$2.1MraisedMar 2015 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven J RoyExecutive Officer, Director
- T. Richard FortDirector
- Steve Bryan WarneckeExecutive Officer, Director
- Mark LupaDirector
- Offering amount
- $6M
- Amount sold
- $2.1M
- Minimum investment
- $10K
- Proceeds to insiders
- $193K
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$587.3KraisedNov 2014 · 21 investors · BiotechnologyRule 506(b)
▶$587.3KraisedNov 2014 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- T. Richard FortDirector
- Steve Bryan WarneckeExecutive Officer, Director
- Steven J RoyExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $587.3K
- Minimum investment
- $10K
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
ImpriMedImpriMedicine provides live-cell-based predictive analytics to identify effective drugs for treating blood cancers in dogs and cats, offering patient-specific drug response predictions. The company serves veterinary oncology and drug development efforts in the animal health field.
Dvm360dvm360 is a veterinary medicine news and education publisher, delivering clinical articles, video shorts, continuing education, and conference coverage for veterinarians, technicians, and practice staff. It also produces a digital edition and reports on industry developments across the veterinary profession.
Companies working in the same space as VetDC.
Frequently asked questions
- What does VetDC do?
- A veterinary pharmaceutical company developing Rabacfosadine, an acyclic nucleotide analogue for treating lymphoma in dogs and cats.
- Who are VetDC's investors?
- VetDC's investors include Keiretsu Forum.
- How much funding has VetDC raised?
- VetDC has disclosed $2.7M raised across 2 rounds.
- Where is VetDC headquartered?
- VetDC is headquartered in Castle Rock, US.